logo-loader
Medusa Mining

Medusa Mining appoints Andrew Teo as interim chief executive officer

The gold producer said Andew Teo will replace managing director and CEO Boyd Timler with the effect from 6 July 2018

handshake
Also, Medusa has appointed Peter Hepburn-Brown as an independent non-executive director

Medusa Mining Ltd (ASX:MML) has announced the appointment of company’s chairman Andrew Teo as interim chief executive officer, while the search for a replacement CEO is undertaken.

The gold producer said Andew Teo will replace managing director and CEO Boyd Timler with the effect from 6 July 2018. Timler retires after more than two years with Medusa due to the extent of the travel requirements associated with the role.

READ: Medusa Mining still on track to hit production guidance of between 85,000 and 95,000 ounces of gold this year

Medusa has also promoted Dave McGowan to the role of chief operating officer. The company said McGowan has worked for Medusa as the general manager-engineering since February 2017 and has more than 35 years’ experience in the mining industry.

Also, Medusa has appointed Peter Hepburn-Brown as an independent non-executive director.

The company said he has more than 37 years of mining experience, including senior management and board positions in Australia and overseas, as well as three years as managing director of Medusa between June 2011 and August 2014.

Andrew Teo, executive chairman, commented on the appointments: “We are delighted to announce the appointment of David as COO and to be welcoming Peter back to the Medusa team.”

He added: “We look forward to the contributions we know David and Peter will make the company."

 

Quick facts: Medusa Mining

Price: $0.90

Market: ASX
Market Cap: $185.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

2 hours, 9 minutes ago

2 min read